Franklin Genomic Advancements ETF (HELX)
36.89
-0.15
(-0.40%)
USD |
BATS |
Dec 09, 14:41
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.50% | -0.04% | 22.23M | 2133.87 |
| Weighted Average Dividend Yield | Turnover Ratio (Generic) | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 0.11% | 33.00% | 7.506M | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks capital appreciation. The Fund invests in equity securities of companies that benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business. |
| General | |
| Security Type | Exchange-Traded Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Franklin Templeton |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of December 09, 2025.
Asset Allocation
As of November 30, 2025.
| Type | % Net |
|---|---|
| Cash | 1.14% |
| Stock | 97.91% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 0.99% |
| Other | -0.03% |
Basic Info
| Investment Strategy | |
| The Fund seeks capital appreciation. The Fund invests in equity securities of companies that benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business. |
| General | |
| Security Type | Exchange-Traded Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Franklin Templeton |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |